The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis

Atherosclerosis

Volumn 141, Issue 1, 1998, Pages 161-166

  Verhoeff, B J ^a   Trip, M D ^a   Prins, M H ^a   Kastelein, J J P ^a   Reitsma, P H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Folate; Homocysteine; Methylenetetrahydrofolate reductase mutation; Premature atherosclerosis; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; HOMOCYSTEINE; METHIONINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CORRELATION FUNCTION; ENVIRONMENTAL FACTOR; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; GENOTYPE; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

ADULT; AGE OF ONSET; ARTERIOSCLEROSIS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; RISK FACTORS; VITAMIN B 12;

EID: 18144447640     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00156-7     Document Type: Article

References (39)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56:1969;111-128.
2. Boers G.H.J. Hyperhomocysteinemia: a newly recognized risk factor for vascular disease. Neth. J. Med. 45:1994;34-41.
3. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulski A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1995;1049-1057.
4. Berwanger C.S., Jeremy J.Y., Stansby G. Homocysteine and vascular disease. Br. J. Surg. 82:1995;726-731.
5. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J. Am. Coll. Card. 27:1996;517-527.
6. Arnesen A., Refsum H.M., Bønaa K.H., Ueland P.M., Førde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:1995;704-709.
7. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W.F., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332:1995;286-291.
8. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., Palma-Reis R.J., Boers G.H.J., Sheahan R.G., Israelsson B., Uiterwaal C.S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J.C., de Valk H.W., Sales Lúis A.C., Parrot-Roulaud F.M., Tan K.S., Higgins I., Garcon D., Medrano M.J., Candito M., Evans A.E., Andria G. Plasma homocysteine as a risk factor for vascular disease-the European concerted action project. J. Am. Med. Assoc. 277:1997;1775-1781.
9. Wong P.W.K., Justice P., Hruby M., Weiss E.B., Diamond E. Folic acid nonresponsive homocystinuria due to methylenetetrahydrofolate reductase deficiency. Pediatrics. 59:1977;749-756.
10. Kang S.S., Wong P.W.K., Bock H.G.O., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am. J. Hum. Genet. 48:1991;546-551.
11. Goyette P.h, Frosst P.h, Rosenblatt D.S., Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am. J. Hum. Genet. 56:1995;1052-1059.
12. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J.H., den Heijer M., Kluijtmans L.A.J., van den Heuvel L.P., Rozen R. A candidate genetis risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
13. Kluijtmans L.A.J., van den Heuvel L.P.W.J., Boers G.H.J., Frosst P., Stevens E.M.B., van Oost B.A., den Heijer M., Trijbels F.J.M., Rozen R., Blom H.J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 58:1996;35-41.
14. Engbersen A.M.T., Franken D.G., Boers G.H.J., Stevens E.M.B., Trijbels F.J.M., Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56:1995;142-150.
15. Kang S.S., Wong P.W.K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 48:1991;536-545.
16. Jacques P.F., Bostom A.G., Williams R.G., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., Selhub J., Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
17. Harmon D.L., Woodside J.V., Yarnell J.W.G., McMaster D., Young I.S., McCrum E.E., Gey K.F., Whitehead A.S., Evans A.E. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinanat of mild hyperhomocysteinemia. Q. J. Med. 89:1996;571-577.
18. Arruda V.R., von Zuben P.M., Chiaparini L.C., Annichino-Bizzacchi J.M., Costa F.F. The mutation ala677val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb. Haemost. 77:1997;818-821.
19. Gallagher P.M., Meleady R., Shields D.C., Tan K.S., McMaster D., Rozen R., Evans A., Graham I.M., Whitehead A.S. Homocysteine and risk of premature coronary heart disease-evidence for a common gene mutation. Circulation. 94:1996;2154-2158.
20. Morita H., Taguchi J., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y., Maemura K., Shindo T., Minamino T., Ohno M., Yamaoki K., Ogasawara K., Aizawa T., Suzuki S., Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
21. Verhoef P., Kok F.J., Kluijtmans L.A.J., Blom H.J., Refsum H., Ueland P.M., Kruyssen D.A.C.M. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 132:1997;105-113.
22. Adams M., Smith P.D., Martin D., Thompson J.R., Lodwick D., Samani N.J. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Q. J. Med. 89:1996;437-444.
23. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J., Malinow R., Willett W.C., Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
24. Brugada R., Marian A.J. A common mutation in methylenetetrahydrofolate reductase gene is not a risk factor of coronary artery disease or myocardial infarction. Atherosclerosis. 128:1997;107-112.
25. Schwartz S.M., Siscovick D.S., Malnow M.R., Rosendaal F.R., Beverly R.K., Hess D.L., Psaty B.M., Longstreth W.T. Jr, Koepsell T.D., Raghunathan T.E., Reitsma P.H. Myocardial infarction in young woman in relation to plasma total homocysteine, folate and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 96:1997;412-417.
26. van Bockxmeer F.M., Mamotte C.D.S., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
27. Deloughery T.G., Evans A., Sadeghi A., McWilliams J., Henner W.D., Taylor L.M., Press R.D. Common mutation in methylenetetrahydrofolate reductase-correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 94:1996;3074-3078.
28. Christensen B., Frosst P.h, Lussier-Cacan S., Selhub J., Goyette P., Rosenblatt D.S., Genest J. Jr, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;569-573.
29. Kang S.S., Wong P.W.K., Norusis M. Homocystinuria due to folate deficiency. Metabolism. 36:1987;458-462.
30. Brattstrom L., Israelsson B., Norrving B., Begqvist D., Thörne J., Hultberg B., Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease-effects of pyridoxine and folic acid treatment. Atherosclerosis. 81:1990;51-60.
31. Selhub J., Jacques P.F., Wilson P.W.F., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J. Am. Med. Assoc. 270:1995;2693-2698.
32. Landgren F., Israelsson B., Lindgren A., Hultberg B., Andersson A., Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J. Int. Med. 237:1995;381-388.
33. Boers G.H.J., Fowler B., Smals A.G.H., Trijbels F.J.M., Leermakers A.I., Kleijer W.J., Kloppenborg P.W.C. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum. Genet. 69:1985;164-169.
34. Ubbink J.B., Vermaak W.J.H., Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J. Chromatogr. 565:1991;441-446.
35. Schrijver J., Speek A.J., Schreurs W.H.P. Fluoromatic determination of pyridoxal-5-phosphate in whole blood by HPLC. Int. J. Vit. Nutr. Res. 51:1981;216-222.
36. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, vol. 9, 2nd ed., NY, USA: Cold Spring Harbor Laboratory, 1989:16-9.
37. den Heijer M., Koster T., Blom H.J., Bos G.M.J., Briët E., Reitsma P.H., Vandenbroucke J.P., Rosendaal F.R. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med. 334:1996;759-762.
38. Tucker K.L., Mahnken B., Wilson P.W.F., Jacques P., Selhub J. Folic acid fortification of the food supply-potential benefits and risks for the elderly population. J. Am. Med. Assoc. 276:1996;1879-1885.
39. Ward M., McNulty H., McPartlin J., Strain J.J., Weir D.G., Scott J.M. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q. J. Med. 90:1997;519-524.